SRP2152
HIV Protease, His tagged,recombinant from HIV-1
recombinant, expressed in E. coli, ≥85% (SDS-PAGE)
Synonym(s):
HIV_retropepsin_like, Retropepsins, cd05482, pepsin-like aspartate proteases
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352204
NACRES:
NA.26
biological source
human immunodeficiency virus 1
recombinant
expressed in E. coli
Assay
≥85% (SDS-PAGE)
form
frozen liquid
mol wt
~11.9 kDa
packaging
pkg of 10 μg
storage condition
avoid repeated freeze/thaw cycles
concentration
200 μg/mL
color
colorless to clear
NCBI accession no.
UniProt accession no.
shipped in
dry ice
storage temp.
−70°C
Related Categories
Application
HIV Protease has been used in in vitro detection of HIV protease activity using FRET-HIV Sensor, a Förster resonance energy transfer-based HIV protease-sensitive sensor.
Biochem/physiol Actions
The HIV-1 core consists of a viral genome housed within a conical viral capsid that is generated during virion maturation. Human immunodeficiency virus type 1 (HIV-1) matures after the viral protease processes the Gag and Pol polyproteins at 10 substrate locations. The protease of HIV-1 is an aspartic protease and is functional only as a dimer; dimerization results in the formation of a binding cleft in which each of the two catalytic aspartic acids is contributed by one of the monomers. Because the protease is active only as a dimer, two of the GagPol precursors must themselves dimerize during virus assembly so that their protease domains can dimerize, become active, and process the precursors. The order and kinetics of cleavage as well as the extent of precursor processing appear to be critical steps in the generation of fully infectious, appropriately assembled viral particles. Inhibition of HIV-1 protease represents an important avenue for antiviral therapy. Currently available combination chemotherapy with reverse transcriptase inhibitors (RTIs) and protease inhibitors (PIs) for human immunodeficiency virus type 1 (HIV-1) infection and AIDS have been shown to suppress the replication of HIV-1 and extend the life expectancy of HIV-1-infected individuals.
Sequence
PQITLWQRPL VTIKIGGQLK EALLDTGADD TVLEEMSLPG RWKPKMIGGI GGFIKVRQYD QILIEICGHK AIGTVLVGPT PVNIIGRNLL TQIGCTLNF
Physical form
Clear and colorless frozen liquid solution
Formulated in 20mM Mes buffer, pH6, 500mM KCl, 20% glycerol.
Preparation Note
Please keep in −20 °C for long term storage. It lost 70% activity in 4°C for one week. Freeze thaw cycle resistance.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. While working, please keep sample on ice.
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
常规特殊物品
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Noninvasive high-throughput single-cell analysis of HIV protease activity using ratiometric flow cytometry.
Gaber R
Sensors (Basel, Switzerland), 13, 16330-16346 (2013)
C Peng et al.
Journal of virology, 63(6), 2550-2556 (1989-06-01)
It is generally believed that the gag gene product of human immunodeficiency virus type 1 (HIV-1) is processed into several core proteins by a virus-specific protease. We used deletion mutation analysis to study the role of HIV-specific protease in the
K C Chou et al.
Proteins, 24(1), 51-72 (1996-01-01)
Based on the sequence-coupled (Markov chain) model and vector-projection principle, a discriminant function method is proposed to predict sites in protein substrates that should be susceptible to cleavage by the HIV-1 protease. The discriminant function is defined by delta =
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service